Co-expression of the C-terminal domain of Yersinia enterocolitica invasin enhances the efficacy of classical swine-fever-vectored vaccine based on human adenovirus.
Loading...
Date
2015-03
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The use of adenovirus vector-based vaccines is a promising approach for generating antigen-specific immune
responses. Improving vaccine potency is necessary in other approaches to address their inadequate protection for
the majority of infectious diseases. This study is the first to reconstruct a recombinant replication-defective human
adenovirus co-expressing E2 and invasin C-terminal (InvC) glycoproteins (rAd-E2-InvC). rAd-E2-InvC with 2×106
TCID50 was intramuscularly administered two times to CSFV-free pigs at 14 day intervals. No adverse clinical
reactions were observed in any of the pigs after the vaccination. The CSFV E2-specific antibody titer was significantly
higher in the rAd-E2-InvC group than that in the rAdV-E2 group as measured by NPLA and blocking ELISA. Pigs
immunized with rAd-E2-InvC were completely protected against lethal challenge. Neither CSFV RNA nor pathological
changes were detected in the tissues after CSFV challenge. These results demonstrate that rAd-E2-InvC could
be an alternative to the existing CSF vaccine. Moreover, InvC that acts as an adjuvant could enhance the immunogenicity
of rAdV-E2 and induce high CSFV E2-specific antibody titer and protection level.
Description
Keywords
Classical swine fever (CSF), E2, human adenovirus, invasin, vaccine
Citation
Li Helin, Ning Pengbo, Lin Zhi, Liang Wulong, Kang Kai, He Lei, Zhang Yanming. Co-expression of the C-terminal domain of Yersinia enterocolitica invasin enhances the efficacy of classical swine-fever-vectored vaccine based on human adenovirus. Journal of Biosciences. 2015 Mar; 40 (1): 79-90.